The distal short arm of chromosome 1 is commonly deleted in a variety of human neoplasms including gastrointestinal cancer. Genetic alterations of the retinoblastoma protein-interacting zing-finger gene (RIZ)1 including loss of heterozygosity (LOH) at 1p36, frameshift mutations, and promoter hypermethylation were reported previously in several cancers. In this study, we evaluated RIZ1 in 30 primary gastric cancers and found frameshift mutations in two cases (6.7%). Moreover, using real-time quantitative methylation-specific PCR, methylation of the RIZ1 promoter was detected in 11 (37%) cases. In all 11 cases with methylation, inactivation of the second allele occurred through frameshift mutation, LOH or promoter methylation. Our results suggest that RIZ1 is a specific target of inactivation in human gastric cancer.
It is well known that silencing of tumor suppressor genes (TSGs) by genetic and epigenetic pathways play a significant role in human carcinogenesis. Two major pathways of genetic instability include gross chromosomal instability and instability of small repetitive DNA sequences called microsatellites. Epigenetic silencing is also considered to be a significant contributor to human carcinogenesis. Silencing of TSGs by methylation of CpG-rich promoter regions has been reported in many kinds of human cancers (Esteller et al., 2001) .
The distal region of the short arm of human chromosome 1 (1p36) is commonly deleted in a variety of human tumors, including gastrointestinal cancer (Weith et al., 1996; Nomoto et al., 2000) . This region is known to harbor several TSGs. One candidate in this region is the retinoblastoma (Rb) protein-interacting zing-finger gene, (RIZ) (PRDM2), initially isolated in a functional screen for Rb-binding proteins (Buyse et al., 1995) . RIZ is a member of the nuclear proteinmethyltransferase (MTase) superfamily. This family of genes is known to play an important role in chromatinmediated regulation of gene expression, development, and cancer. RIZ contains a novel protein methyltransferase domain, called the PR (PRDI-BFI-RIZ) domain or SET (Suvar3-9, Enhancer-of-zeste, Trithorax) domain, the canonical Rb-binding motif LXCXE, the nuclear hormone receptor-binding motif LXXLL, and eight zinc-finger motifs. PR family members that differ by the presence or absence of the PR domain generally produce two products. RIZ1 contains a PR domain thought to function in tumor suppression and RIZ2 lacks this motif. RIZ1 expression, but not RIZ2, is commonly decreased or silenced in human tumors and adenovirus-mediated RIZ1 expression causes G2/M cell cycle arrest and/or apoptosis in breast cancer, liver cancer, and mismatch repair-deficient colon cancer (Jiang et al., 1999; Chadwick et al., 2000) .
Frequent frameshift mutations of the RIZ1 gene are common in cancers of the colon, stomach, and pancreas with microsatellite instability (Chadwick et al., 2000; Sakurada et al., 2001) . These mutations are located at two polyadenosine tracts in exon 8; one (A)8 tract at coding nucleotide position 4273-4280 and one (A)9 tract at 4462-4471. One or 2-bp deletions in these tracts generate truncated RIZ1 proteins lacking the PRbinding motif and are proposed to have serious effects on the PR domain-specific function of RIZ1. Although missense mutations in the PR domain were not found in liver cancers , a focused mutational analysis in the RIZ1-specific PR domain region discovered several missense mutations in diffuse large Bcell lymphoma (Steele-Perkins et al., 2001) . However, no mutations were reported in other major solid tumors.
Silencing of TSGs by methylation of 5 0 CpG islands is now recognized as a common feature of human carcinogenesis including gastric cancer (Jones and Laird, 1999; Toyota et al., 1999) . Recently, Du et al. (2001) cloned the RIZ1 promoter and found that hypermethylation of the RIZ1 promoter correlated with lost or decreased RIZ1 mRNA expression in breast, liver, colon, and lung cancer cell lines. We thus examined the methylation status of the RIZ1 promoter in gastric cancer by using real-time quantitative methylation-specific PCR (MSP) assay. This method is based on the continuous optical monitoring of a fluorogenic PCR (Eads et al., 2000) and may be more specific because of the use of an internally binding fluorogenic hybridization probe.
We first tested 30 primary gastric cancers and normal mucosa DNA samples for loss of heterozygosity (LOH) by using three microsatellite markers. The RIZ CA marker located within the RIZ gene showed LOH in six cases (20.0%) ( Table 1 ; representative case shown in Figure 1c ). In addition, we used two other microsatellite markers (D1S489 and D1S507) to obtain LOH information in the same region for RIZ CA noninformative cases. Allelic imbalance in one or more markers was observed in 10 (33.3%) of the 30 cases. Microsatellite instability (MSI) was observed in six cases (20.0%) in at least one of the three markers (Table 1 ; representative case shown in Figure 1d ). A review of previous papers described a frequency of 1p deletion that ranged from 22 to 89%, with an average of close to 30% of gastric tumors (Schwab et al., 1996) . Our LOH analysis is thus in agreement with previous reports.
We detected RIZ1 frameshift mutations in two (6.7%) of the 30 cases (Table 1 ; representative case shown in Figure 1e ) and both targeted the (A)9 track. DNA purified from the mutated bands in the gel showed a 1-bp deletion at the (A)9 track by sequence analysis (data not shown). Both frameshifts were found in microsatellite unstable cases, as such, 33.3% of MSI (+) cases (2/6) harbored these alterations. These frameshift mutations are likely to result in the production of COOH-terminal domain truncated proteins. Truncated proteins lack a PR domain-binding motif, which plays an important role in RIZ1 folding and binding to other proteins including RIZ1 itself. Thus these frameshift mutations are thought to affect seriously RIZ1 function. Piao et al. (2000) reported frameshift mutations in 19 (48%) of the 40 MSI-positive gastric cancers, while Sakurada et al. (2001) described these changes in four (36%) of the 11 MSI-high gastric cancer samples. Thus, we confirmed a similar frequency of these mutations in MSI (+) gastric cancer compared to previous reports. , 1997) . Tumor samples and corresponding normal samples were immediately fresh-frozen after resection and stored at À801C. Tumor and normal sample DNA was prepared as described previously (Nawroz et al., 1996) N, normal sample; T, tumor sample; diffuse (s) diffuse signet-cell type; ND, not detected; LOH, loss of heterozygosity; MSI, microsatellite instability; retain, retention of heterozygosity; NI, not informative , and 24 (f). Real-time quantitative MSP was performed as described previously (Usadel et al., 2002) . The fluorogenic probes were custom synthesized by Perkin-Elmer Applied Biosystems. The amplicon size of the RIZ1 promoter MSP assay was 121 bp (position 397-517, deposited at GenBank as Accession number AF 472587). The sequences of the primers and probe used to amplify and detect methylated RIZ1 were 5 0 -GGATTCGCGGTGATTTACGA-3 0 (sense), 6FAM-CGACGGCGTAGGGTTAAGGGTCG-TAMRA (probe), and 5 0 -CTAC-GAAACTAAAAAACTCCGAAACC-3 0 (antisense). The sequences for b-actin, used as the internal reference gene, were 5 0 -TGGTGATGGAGGAGGTTTAGTAAGT-3 0 (sense), 6FAM-ACCACCACCCAACACACAATAACAAACACA-TAMRA (probe), and 5 0 -AACCAATAAAACCTACTCCTCCCTTAA-3 0 (antisense). Amplifications were carried out in 384-well plates in a 7900 Sequence detector (Perkin-Elmer Applied Biosystems). All samples were run in duplicate and repeated in quadruple if not identical. Each plate included multiple water blanks, a negative control and serial dilutions of a positive control for constructing the calibration curve on each plate. Lymphocyte DNA from a healthy individual was used as the negative control for the RIZ1 gene. The same lymphocyte DNA was methylated in vitro with excess Sss I Methyltransferase (New England Biolabs, Inc., Beverly, MA, USA) to generate completely methylated DNA at all CpGs and used as the positive control. PCR amplification with the aid of oligonucleotide primers based on sequences that were obtained either via on-line servers or from previous reports (Nomoto et al., 2000) was performed containing [
32 P]dCTP, and 100 ng of genomic DNA PCR. We used three markers; RIZ CA is a CA repeat located within the intron preceding exon 5 of RIZ1. The other two markers, D1S489 and D1S507, were telomeric and centromeric from the RIZ locus, respectively, and used to obtain LOH information in cases where RIZ CA was not informative cases. PCR products were analysed on a denaturing 6% polyacrylamide gel and processed by autoradiography. Allelic loss was scored when the band intensity of one allelic marker was decreased significantly (more than 50% reduction) in tumor DNA as compared with that in the normal DNA. Frameshift mutations at (A)8 and (A)9 tracks in the RIZ1 coding region were detected by the PCR assay described previously . The (A)8 track was amplified with primers, 5 0 -GAGCTCAGCAAAATGTCGTC-3 0 (sense) and 5 0 -CAAGTCGGCCTTCTGCTTTG-3 0 (antisense). The (A)9 track was amplified with primers, 5 0 -TCTCACATCTGCCCTTACTG-3 0 (sense) and 5 0 -GTGATGAGTGTC-CACCTTTC-3 0 (antisense). Annealing temperatures for these PCR amplification were 601C. RT-PCR analysis was performed as described previously (Esteller et al., 2000) . Total RNA (2 mg) isolated from the primary gastric cancers and normal mucosa were used to generate cDNA and then amplified by PCR with primers for RIZ1, 5 0 -TGGGGGTAGGTAGGTCACTT-3 0 (sense) and 5 0 -GGCACGGAAGGAGGTAGAAA-3 0 (antisense), which amplify a 325-bp product and for GAPDH, 5 0 -TCTTCCAGGAGCGA-GATCC-3 0 (sense) and 5 We then examined these tumors for hypermethylation of the RIZ1 promoter. Although conventional MSP is widely used to detect methylation, we used a real-time quantitative MSP assay in this study. This MSP assay has a 10-fold greater sensitivity compared to conventional MSP (Eads et al., 2000; Usadel et al., 2002) and greater specificity because of the use of an internally binding fluorogenic hybridization probe. Methylation of the RIZ1 promoter was detected by real-time quantitative MSP in 11 (37%) of the 30 gastric cancer tissues (Table 1 ; representative cases shown in Figure 1a ,b). RIZ1 methylation was also detected in six normal mucosa samples even though the methylation ratio of normal samples was very low. Template quantity can be derived from the cycle number at which the amplification plot crosses a threshold in the exponential phase of the PCR reaction. We thus compared the methylation quantities between tumor and normal mucosa samples by using the methylation ratio (Figure 2 ). The median methylation ratio was 11.99 in the tumor samples and 1.50 in the normal samples. Statistical analysis of the data using the Mann-Whitney U-test revealed a significant difference in the methylation ratio between tumor and normal samples (Po0.01). DNA methylation of normal tissues has been reported previously including noncancerous gastric mucosa (Esteller et al., 2000; Tsuchiya et al., 2000) . There are several possible explanations for the detection of methylation in the normal mucosa samples. This methylation may be because of the infiltration of neoplastic or inflammatory cells in the surrounding tissue. The normal mucosa, which was confirmed as histologically normal, may be damaged by environmental factors such as smoking and already harbor transformed regions because of early molecular events. Although one normal tissue sample displayed a higher level of RIZ1 methylation (ratio about 30%), no obvious cancer cells were found in the specimen. It is possible that transformed cells without morphologic alterations spread beyond the primary tumor site. Alternatively, methylation of certain genes has been shown to increase in aging tissues. In our study, the median age of methylated and nonmethylated normal mucosa samples was not significantly different (72 vs 61 years old). Further work is needed to clarify the significance of low-level mucosal methylation in normal mucosa.
We then examined the expression of the RIZ1 by RT-PCR (Figure 1f ). We were able to extract RNA from 26 cases. Three of the four cases harboring biallelic inactivation (methylation + LOH or methylation + mutation) showed silenced or decreased expression of RIZ1 in cancer samples. In addition, three of the six cases harboring high levels of methylation (probably containing two methylated alleles) showed decreased expression. Interestingly, two cases without alterations showed decreased expression (cases nine and 24), suggesting other pathways for decreasing RIZ1 gene expression in addition to the genetic and epigenetic mechanisms tested here.
Silencing or decreased RIZ1 gene expression appears to be a common event in human cancers. Clearly, hypermethylation appears to be a common mechanism for the inactivation of RIZ1 in gastric cancer. For some TSGs, a common mechanism of inactivation may be DNA hypermethylation and RIZ1 may belong to such a group (Du et al., 2001) . In this study, more than onethird of primary gastric cancers harbored complete RIZ1 inactivation. Our results thus support inactivation of RIZ1 as a specific target in human gastric cancer. Figure 2 Real-time quantitative MSP quantifications of normal mucosa (N) and gastric cancer (T) were expressed as a methylation ratio, defined as the ratio of the fluorescence intensity values for the RIZ1 to those of the b-actin, multiplied by 100. The median methylation ratios, which are shown as horizontal bars within each group, were 1.50 in normal samples and 11.99 in tumor samples. All samples were classified as negative if the RIZ1 methylation ratio was o10.0%. We determined the medians and ranges of the methylation ratios for tumor and normal tissue samples. Using the Mann-Whitney U-test and P-values less than 0.05 were considered to be significant tested associations between these values. Analyses were carried out using the StatView software package (SAS Cary, NC, USA)
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